B-Cell Lymphoma Pipeline Accelerates as 295+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight's, "B-cell Lymphoma Pipeline Insight 2026" report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma pipeline landscape. It covers the B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the B-Cell Lymphoma Pipeline @ https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the B-Cell Lymphoma Pipeline Report
• On July 24, 2026- Alliance Foundation Trials LLC highlighted a study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary objective of the study being to assess median PFS and the secondary objectives to include ORR, CR, DOR, OS and toxicity. Subjects will be enrolled and treated with palbociclib and ibrutinib with each cycle of therapy being 28 days. Treatment will be based on the recommended phase II dose (RP2D) from the phase I combination trial.
• On July 22, 2026- BeOne Medicines initiated a phase 3 study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
• On July 22, 2026- Memorial Sloan Kettering Cancer Center conducted a study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. The treatment being tested in this study is glofitamab, polatuzumab, and obinutuzumab in combination with standard treatment (the combination of rituximab, cyclophosphamide, doxorubicin, and prednisone, or R-miniCHP).
• On July 20, 2026- Hoffmann-La Roche announced a phase II Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.
• DelveInsight's B-Cell Lymphoma pipeline report depicts a robust space with 295+ active players working to develop 300+ pipeline therapies for B-Cell Lymphoma treatment.
• The leading B-Cell Lymphoma Companies such as Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc., Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, HUTCHMED and others.
• Promising B-Cell Lymphoma Pipeline Therapies such as Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.

Stay ahead with the most recent pipeline outlook for B-Cell Lymphoma @ https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

B-cell Lymphoma Overview
B-cell lymphoma is a type of non-Hodgkin lymphoma (NHL) that arises from B lymphocytes, which are a type of white blood cell responsible for producing antibodies to fight infections. B-cell lymphomas account for about 85% of all NHL cases and encompass a variety of subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. Each subtype has distinct clinical behaviors, but in general, B-cell lymphomas are characterized by abnormal proliferation of B-cells in the lymphatic system, often involving the lymph nodes, spleen, and bone marrow.

B-Cell Lymphoma Emerging Drugs Profile
• Lisocabtagene maraleucel: Bristol Myers Squibb
Lisocabtagene maraleucelis a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells. It is made from a patient's own T cells, which are collected and genetically reengineered to become CAR T cells that are then delivered via infusion as a one-time treatment. Breyanzi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal LBCL, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy, or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplant due to comorbidities or age, or relapsed or refractory disease after two or more lines of systemic therapy. The drug is currently in Phase III stage of development for treatment of B cell lymphoma.

• Glofitamab: Hoffmann-La Roche
Glofitamab is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T-cells and CD20 on the surface of B-cells. The drug candidate was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T-cells, a type of immune cell, and two regions that bind to CD20, a protein on B-cells, which can be healthy or malignant. This dual-targeting brings the T-cell in close proximity to the B-cell, activating the release of cancer cell-killing proteins from the T-cell. Columvi is part of Roche's broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development programme that also includes Lunsumio® (mosunetuzumab), which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems. Roche is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma (DLBCL) and other blood cancers. The drug is currently in Phase III stage of development for treatment of B cell lymphoma.

• NKTR-255: Nektar Therapeutics
NKTR-255 is an investigational drug developed by Nektar Therapeutics, designed as a polymer-conjugated interleukin-15 (IL-15) receptor agonist. Its primary goal is to enhance the immune system's capacity to combat cancer by boosting the proliferation and survival of natural killer (NK) cells and memory CD8+ T cells. This mechanism involves engaging the entire IL-15 receptor complex, which may lead to the formation of long-term immunological memory and a sustained anti-tumor immune response. The drug is currently in Phase II/III stage of development for treatment of B cell lymphoma.

• Zamtocabtagene autoleucel: Miltenyi Biomedicine GmbH
Zamtocabtagene autoleucel, also known as MB-CART2019.1, is an investigational chimeric antigen receptor T-cell (CAR-T) therapy developed by Miltenyi Biotec. This therapy targets both CD19 and CD20 antigens, making it a bispecific treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Zamtocabtagene autoleucel is designed to enhance the immune response against B-cell tumors by utilizing genetically modified T cells that express CARs targeting both CD19 and CD20. The therapy employs a lentiviral vector to transduce autologous T cells, which are then expanded and infused back into the patient after lymphodepleting chemotherapy. This dual targeting approach aims to overcome resistance mechanisms associated with single-target therapies, particularly in cases where the tumor may lose expression of one of the targets. The drug is currently in Phase II stage of development for treatment of B cell lymphoma.

• MB-CART20.1: Miltenyi Biomedicine GmbH
MB-CART20.1 is an investigational CAR-T cell therapy engineered to target the CD20 protein, which is highly expressed on the surface of B-cells in certain cancers, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. By modifying a patient's T-cells to express chimeric antigen receptors (CARs) that recognize CD20, MB-CART20.1 enables the immune system to selectively attack and eliminate cancerous B-cells. This therapy is designed to offer a novel option for patients with relapsed or refractory CD20-positive malignancies, aiming to improve outcomes through enhanced tumor targeting and prolonged remission. Clinical trials are ongoing to assess its efficacy and safety. The drug is currently in Phase I/II stage of development for treatment of B cell lymphoma.

• AVM0703: AVM Biotechnology
AVM0703 is a clinical-stage therapeutic that works by rapidly inducing the production and release of endogenous bispecific gamma delta TCR+ and invariant TCR+ Natural Killer T-like cells (AVM-NKT), which possess unique immune properties. Following a single dose of AVM0703, these supercharged immune cells appear in the bloodstream and target abnormal cells, including cancer cells, infected cells, and autoreactive lymphocytes. AVM0703's mechanism is based on a proprietary suprapharmacologic dose of dexamethasone, designed to deliver high doses without typical side effects. This enhanced dexamethasone formulation triggers the activation and mobilization of AVM-NKT cells, offering a potent yet gentler treatment option by targeting malignancies and immune disorders with precision. The drug is currently in Phase I/II stage of development for treatment of B cell lymphoma.

• LBS-007: Lin BioScience, Inc
LBS-007 is a novel targeted therapy for the treatment of a broad array of cancers. It has demonstrated activity against leukemia and solid tumors, especially in chemotherapy-resistant cell lines and other cancer cell lines. LBS-007 has obtained Orphan Drug Destination (ODD) for Acute Lymphoma Leukemia (ALL) from US FDA in 2018/March and entered a first-in-human Phase I/II trial. LBS-007 inhibits cancer cell replication by interrupting the S phase of the cell cycle. Its mechanism of action is to inhibit a key regulator protein of the cell cycle, CDC7. Inhibition of CDC7 stops the proliferation of tumor cells and results in cancer cell death. Because CDC7's activity is often upregulated in cancer cells in comparison to healthy cells, it's an ideal candidate for a targeted anti-cancer therapy. The drug is currently in Preclinical stage of development for treatment of B cell lymphoma.

The B-Cell Lymphoma Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Lymphoma Treatment.
• B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Lymphoma market

Explore groundbreaking therapies and clinical trials in the B-Cell Lymphoma Pipeline @ https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

B-Cell Lymphoma Companies
Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc., Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, HUTCHMED and others.

B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

B-Cell Lymphoma Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of B-Cell Lymphoma Treatment. Learn about new drugs, pipeline developments @ https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the B-Cell Lymphoma Pipeline Report
• Coverage- Global
• B-Cell Lymphoma Companies- Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc., Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, HUTCHMED and others.
• B-Cell Lymphoma Pipeline Therapies- Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.
• B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on B-Cell Lymphoma Therapies and clinical trials @ B-Cell Lymphoma Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. B-Cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. B-Cell Lymphoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Lisocabtagene maraleucel: Bristol Myers Squibb
9. Mid Stage Products (Phase II)
10. Zamtocabtagene autoleucel: Miltenyi Biomedicine GmbH
11. Early Stage Products (Phase I/II)
12. MB-CART20.1: Miltenyi Biomedicine GmbH
13. Preclinical and Discovery Stage Products
14. LBS-007: Lin BioScience, Inc
15. Inactive Products
16. B-Cell Lymphoma Key Companies
17. B-Cell Lymphoma Key Products
18. B-Cell Lymphoma- Unmet Needs
19. B-Cell Lymphoma- Market Drivers and Barriers
20. B-Cell Lymphoma- Future Perspectives and Conclusion
21. B-Cell Lymphoma Analyst Views
22. B-Cell Lymphoma Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.